Potential role of platelet activating factor in acute renal failure

Kidney International

Volumn 55, Issue 5, 1999, Pages 1672-1682

  Löpez Novoa, José M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Acetylated alkyl phosphoglycerides; Glomerular filtration rate; Hemodynamics; PAF; Renal injury

Indexed keywords

1 [2 [[5 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]QUINOLINIUM; 2,5 BIS(3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; 2,5 BIS(3,4,5 TRIMETHOXYPHENYL)TETRAHYDROTHIOPHENE; 3 (3 PYRIDYL) 1H,3H PYRROLO[1,2 C]THIAZOLE 7 CARBOXAMIDE; 6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; ALPRAZOLAM; APAFANT; BN 5021; CYCLOSPORIN A; GINKGOLIDE; GINKGOLIDE B; HISTAMINE; PROSTAGLANDIN SYNTHASE; SRI 63675; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ENDOTOXEMIA; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEMODYNAMICS; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY ISCHEMIA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; VASOCONSTRICTION; VASODILATATION; XENOGRAFT;

EID: 0032893545     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00450.x     Document Type: Article

References (105)

1. 1. HOSTETTER TH, BRENNER BM: Renal circulatory and nephron function in experimental acute renal failure, in Acute Renal Failure (2nd ed), edited by Brenner BM, Lazarus JM, New York, Churchill, 1988, pp 67-89
2. 2. BENVENISTE J, HENSON PM, COCHIANEL G: Leukocyte dependent histamine release from rabbit platelets: The role of PGE, basophils and a platelet-activating factor. J Exp Med 136:1356-1377, 1972
3. 3. DEMOPOULOS CA, PINCKARD RN, HANAHAN DJ: Platelet-activating factor: Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine as the active components. J Biol Chetn 254:9355-9358, 1979
4. 4. CAMUSSI G: Potential role of platelet activating factor in renal pathophysiology. Kidney Int 29:469-477, 1986
5. 5. SCHLONDORFF D, NEUWIRTH R: Platelet-activating factor and the kidney. Am J Physiol 251:F1-F11, 1986
6. 6. EVANS RD, LUND P, WILLIAMSON DH: Platelet-activating factor and its metabolic effects. Prostaglandins Leukot Essent Fatty Acids 44:1-10, 1991
7. 7. BESSIN P, BONNET J, APFFEL D, SOULARD C, DESGROUX L, PELAS I, BENVENISTE J: Acute circulatory collapse caused by platelet activating factor (PAF-acether) in dogs. Eur J Pharmacol 86:403-413, 1983
8. 8. FEUERSTEIN G, BOYD LM, EZRA D, GOLDSTEIN RE: Effect of platelet activating factor on coronary circulation of the domestic pig. Am J Physiol 246:H466-H471, 1984
9. 9. HUMPHREY DM, MCMANUS LM, SATOUCHI K, HANAHAN DJ, PINCKARD RN: Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest 46:422-427, 1982
10. 10. KENZORA JL, PEREZ JE, BERGMANN SR, LANGE LG: Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload and contractility in dogs. J Clin Invest 74:1193-1203, 1984
11. 11. HEBERT RL, SIROIS P, BRAQUET P, PLANTE GE: Hemodynamic effects of PAF-acether in the dog kidney. Prostaglandins Leukot Med 26:189-202, 1987
12. 12. SANTOS JC, SANZ E, CARAMELO C, LÖPEZ-NOVOA JM: Effect of intrarenal infusion of synthetic PAF-acether in dogs. Rev Esp Fisiol 44:273-278, 1988
13. 13. BADR KF, DEBOER DK, TAKAHASHI K, HARRIS RC, FOGO A, JACOBSON HR: Glomerular responses to platelet-activating factor in the rat: Role of thromboxane A2. Am J Physiol 256:F35-F43, 1989
14. 14. YOO J, SCHLONDORFF D, NEUGARTEN J: Thromboxane mediates the renal hemodynamic effect of platelet activating factor. J Pharmacol Exp Ther 253:743-748, 1990
15. 15. HANDA RK, STRANDHOY JW, BUCKALEW VM JR: Platelet activating factor is a vasodilator in the anesthetized rat. Am J Physiol 258:F1504-F1509, 1990
16. 16. SCHWERTSCHLAG U, SCHERF H, GERBER JG, MATHIAS M, NIES AS: L-platelet activating factor induces changes on renal vascular resistance, vascular reactivity and renin release in the isolated perfused rat kidney. Circ Res 60:534-539, 1987
17. 17. SCHWERTSCHLAG US, DENNIS VW, TUCKER JA, CAMUSSI G: Non-immunological alterations of glomerular filtration rate by s-PAF in the rat kidney. Kidney Int 34:779-785, 1988
18. 18. JUNCOS JA, REN YL, ARIMA S, ITO S: Vasodilator and constrictor actions of platelet-activator factor in the isolated microperfused afferent arteriole of the rabbit kidney: Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products. J Clin Invest 91:1374-1379, 1993
19. 19. CARAMELO C, FERNANDEZ-GALLARDO S, IÑARREA P, SANTOS JC, LÖPEZ-NOVOA JM, SANCHEZ CRESPO M: Presence of platelet activating factor in blood from humans and experimental animals: Its absence in anephric individuals. Biochem Biophys Res Commun 120:789-796, 1984
20. 20. SANCHEZ-CRESPO M, IÑARREA P, ALVAREZ V, ALONSO F, EGIDO J, HERNANDO L: Presence in normal urine of a hypotensive and platelet activating phospholipid. Am J Physiol 244:F706-F711, 1983
21. 21. TSELEPIS A, PINCKARD NR: PAF-acetylhydrolase: A novel enzyme with biochemical and clinical interest. Clin Chem Enzyme Commun 4:279-290, 1992
22. 22. RENOOIJ W, SNYDER F: Biosynthesis of 1-O-alkyl-2-acetyl-sn-gly-cero-3-phosphocholine (platelet activating factor and hypotensive lipid) by cholinephosphotransferase in various rat tissues. Biochim Biophys Acta 663:545-556, 1981
23. 23. PIROTZKY E, BIDAULT J, BURTIN C, GUBLER MC, BENVENISTE J: Release of platelet activating factor, slow reacting substance and vasoactive amines from isolated rat kidneys. Kidney Int 25:404-410, 1984
24. 24. NIES AS, TUNNEY A, BARDEN A, STURM MN, VANDONGEN R: Release of platelet activating factor by the isolated rat kidney is not linked to the production of prostaglandins. J Pharmacol Exp Ther 259:590-594, 1991
25. 25. MUIRHEAD EM, GERMAIN GS, ARMSTRONG FB, BROOKS B, LEACH BE, BYERS LW, PITCOCK JA, BROWN P: Endocrine type antihypertensive function of renomedullary interstitial cells. Kidney Int 8:271-282, 1975
26. 26. SCHLONDORFF D, GOLDWASSER P, NEUWIRTH R, SATRIANO JA, CLAY KL: Production of platelet activating factor in glomeruli and cultured mesangial cells. Am J Physiol 250:F1123-F1127, 1986
27. 27. PIROTZKI E, NINIO E, BIDAULT J, PFISTER A, BENVENISTE J: Biosynthesis of platelet activating factor L. VI. Precursor of platelet-activating factor and acetyl transferase activity in isolated rat kidney cells. Lab Invest 5:567-572, 1984
28. 28. BURGERS JA, AKKERMAN J-WN: Measurement of platelet activating factor in biological specimens. J Lipid Med 3:241-248, 1991
29. 29. BRAQUET P, TOUQUI L, SHEN TY, VARGAFTIG BB: Perspectives in platelet activating factor research. Pharmacol Rev 39:97-145, 1987
30. 30. BRAQUET P: The ginkgolides, potent platelet activating factor antagonists isolated from ginkgo biloba L: Chemistry, pharmacology and clinical applications. Drugs Future 12:643-699, 1987
31. 31. LOPEZ-FARRÉ A, RAMÓN Y CAJAL S, BRAQUET P, LÓPEZ-NOVOA JM: Platelet-activating factor antagonists protect against postischemic acute renal failure in rats. J Pharmacol Exp Ther 253:328-333, 1990
32. 32. LOPEZ-FARRÉ A, TORRALBO M, LÓPEZ-NOVOA JM: Enhanced production of PAF in glomeruli from rats after renal ischemia. Biochem Biophys Res Commun 152:129-135, 1988
33. 33. MONTRUCCHIO G, ALBATTI G, TETTA C, DE LUCA R, SAUNDERS RN, EMANUELLI G, CAMUSSI G: Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol 256:H1236-H1246, 1989
34. 34. FILEP J, HERMAN F, BRAQUET P, MÖZES T: Increased levels of platelet-activating factor in blood following intestinal ischemia in the dog. Biochem Biophys Res Commun 158:353-359, 1989
35. 35. LÓPEZ-FARRÉ A, GOMEZ-GARRE DN, BERNABEU F, PEREZ-RODRIGO P, RAMÖN Y CAJAL S, BRAQUET P, LO ́PEZ-NOVOA JM: Platelet activating factor mediates glycerol-induced acute renal failure in rats. Clin Sci 79:551-558, 1990
36. 36. PLANTE GE, SIROIS P, BRAQUET P: Platelet activating factor antagonism with BN 52021 protects the kidney against acute ischemic injury. Prostaglandins Leukot Essent Fatty Acids 34:53-60, 1988
37. 37. TORRAS J, BORDALBA JR, SERON D, MOLINER R, CARRERA M, VALLES J, NARTINEZ-CASTELAO A, ALSINA J, GRIÑO JM: Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. Transplant Int 6:236-238, 1993
38. 38. YIN M, KURVERS HA, BUUMAN WA, TANGELDER GJ, BOOSTER MH, DAEMEN JH, KONDRACKI S, KOOSTRA G: Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. Transplant Proc 27:774-776, 1995
39. 39. GONZALEZ-FAJARDO JA, FERNANDEZ L, ALVAREZ T, AGUIRRE B, RAMOS G, VAQUERO C: Protective effect of a platelet activating factor antagonist (WEB-2086) in postischemic renal failure. Ann Vasc Surg 10:16-21, 1966
40. 40. KELLY KJ, TOLKOFF-RUBIN NE, RUBIN NH, WILLIAMS WW JR, MEEHAN SM, MESCHTER CL, CHRISTENSON JG, BONVENTRE JV: An oral platelet activating factor antagonist, Ro-24-476, protects the rat kidney from ischemic injury. Am J Physiol 271:F1061-F1067, 1996
41. 41. RIERA M, TORRAS J, HERRERO I, VALLES J, PAUBERT-BRAQUET M, CRUZADO JN, ALSINA J, GRIÑO JM: Neutrophils accentuate renal cold ischemia-reperfusion injury: Dose-dependent protective effect of a platelet-activating factor receptor antagonist. J Pharmacol Exp Ther 280:786-794, 1997
42. 42. YIN M, BUURMAN WA, DAEMEN JW, KOOTSTRA G: The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 245-hour preserved rat kidneys with long warm ischemia. Transplantation 61:1443-1446, 1996
43. 43. HOMSI E, OLIVEIRA-DIAS EP, GRACIA WE, GONTIJO JA, FIGUEIREDO JF: Effects of nifedipine and platelet activating factor antagonist (BN-52021) in glycerol-induced acute renal failure in rats. Renal Fail 18:883-892, 1996
44. 44. FIRTH JD, RATCLIFFE PJ, RAINE AEG, LEDINGHAM JGG: Endothelin: An important factor in acute renal failure. Lancet 2:1179-1181, 1988
45. 45. LÓPEZ-FARRÉ A, GOMEZ-GARRE DN, BERNABEU F, LÓPEZ-NOVOA JM: A role for endothelin in the maintenance of postischemic acute renal failure. J Physiol 444:513-522, 1991
46. 46. LÓPEZ-FARRÉ A, GOMEZ-GARRE DN, BERNABEU F, MONTAÑÉS I, MILLÁS I, LÓPEZ-NOVOA JM: Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. Kidney Int 39:624-630, 1991
47. 47. CAMUSSI G, AGLIETTA M, MALAVASI F, TETTA C, PIACIBELLO W, SANAVIO F, BUSSOLINO F: The release of platelet-activating factor from human endothelial cells in culture. J Immunol 131:2397-2403, 1983
48. 48. MONTERO A, RODRIGUEZ-BARBERO A, LÓPEZ-NOVOA JM: A role for platelet activating factor in endothelin-1-induced mesangial cell proliferation. Eur J Pharmacol 243:235-240, 1993
49. 49. PALLER MS, HOIDAL JR, FERRIS TF: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 74:1156-1164, 1984
50. 50. DUQUE I, GARCÍA ESCRIBANO C, RODRIGUEZ-PUYOL D, DIÉZ-MARQUÉS ML, LÓPEZ-NOVOA JM, ARRIBAS I, HERNANDO L, RODRIGUEZ-PUYOL D: Effects of reactive oxygen species on cultured rat mesangial cells and isolated rat glomeruli. Am J Physiol 263:F466-F473, 1992
51. 51. SANTOS OFP, BOIM MA, BREGMAN R, DRAIBE SA, BARROS EJG, PIROTZKY E, SCHOR N, BRAQUET P: Effect of platelet activating factor antagonist on cyclosporin nephrotoxicity: Glomerular hemodynamics evaluation. Transplantation 47:592-595, 1989
52. 52. PIROTZKY E, COLLIEZ P, GUILMARD C, SCHAEVERBEKE J, BRAQUET P: Cyclosporine-induced nephrotoxicity: Preventive effect of a PAF-acether antagonist, BN 52063. Transplant Proc 20(Suppl 3):665-669, 1988
53. 53. BAGNIS C, DERAY G, DUBOIS M, PIROTZKY E, JACQUIAUD C, BAGHOS W, AUPETIT B, BRAQUET P, JACOBS C: Prevention of cyclosporin nephrotoxicity with a platelet-activator factor antagonist. Nephrol Dial Transplant 11:507-513, 1996
54. 54. LANESE DM, FALK SA, CONGER JD: Sequential agonist activation and site-specific mediation of acute cyclosporin constriction in rat renal arterioles. Transplantation 58:1373-1378, 1994
55. 55. MASSICOT F, WARNET JM, DUTERTRE-CATELLA H, MARTIN C, BRAQUET P, CLAUDE JR: Protection against cyclosporin-induced nephrotoxicity. 1. Effect off a PAF antagonist BN50276. J Lipid Med Cell Signal 9:217-224, 1994
56. 56. MASSICOT F, LAMOURI A, MARTIN C, PHAM-HUY C, HEYMANS F, WARNET JM, GODFROID JJ, CLAUDE JR: Preventive effects of two PAF antagonists PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injury. J Lipid Med Cell Signal 15:203-214, 1997
57. 57. RODRIGUEZ-PUYOL D, LAMAS S, OLIVERA A, ORTEGA G, LÓPEZ-FARRÉ A, HERNANDO L, LÓPEZ-NOVOA JM: Actions of cyclosporin A on cultured rat mesangial cells. Kidney Int 35:632-638, 1989
58. 58. PAVAO DOS SANTOS OF, BOIM M, BARROS EJG, SCHOR N: Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 40:742-747, 1991
59. 59. RODRIGUEZ-BARBERO A, BOSQUE E, RIVAS-CABAÑERO L, ARÉVALO M, LÓPEZ-NOVOA JM: Effect of platelet activating factor antagonist on gentamicin nephrotoxicity. Med Inflamm 1:23-26, 1992
60. 60. RODRIGUEZ-BARBERO A, LÓPEZ-NOVOA JM, AREVALO M: Role of PAF in gentamicin-induced renal failure. Exp Nephrol 5:47-54, 1997
61. 61. RODRIGUEZ-BARBERO AM, RODRIGUEZ-LÓPEZ R, GONZALEZ-SARMIENTO R, LÓPEZ-NOVOA JM: Gentamicin activates rat mesangial cells: A role for platelet activating factor A. Kidney Int 47:1346-1353, 1995
62. 62. RODRÍGUEZ-BARBERO A, MARTÍNEZ-SALGADO C, RODRÍGUEZ-PUYOL D, PÉREZ DE LEMA G, LÓPEZ-NOVOA JM: Involvement of phospholipase A2 in gentamicin-induced rat mesangial cell activation. Am J Physiol 273:F60-F66, 1997
63. 63. WINSTON JA, SAFIRSTEIN R: Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490-F496, 1985
64. 64. PIROTZKY E, GUILMARD C, SIDOTI C, IVANOW F, PRINCIPE P, BRAQUET P: Platelet activating factor antagonist, BN-52021 protects against cis-diamminedichloroplatinum nephrotoxicity in the rat. Renal Fail 12:171-176, 1990
65. 65. FREICHE JC, LANG J, SEDIVY P, TOURAINE JL: Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist. Transplantation 50:8-13, 1990
66. 66. BERGMANN R, SAUMWEBER DM, BRECHT HM, HAMMAER C: Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogenic rejection in ex vivo perfused kidneys. Transplant Proc 22:2009-2010, 1990
67. 67. SAUMWEBER DM, BERGMANN R, GOKEL M, HAMMER C: Hyperacute rejection in an ex vivo model of renal xenografting: Role of the mediator response and its pharmacological manipulation by the specific platelet-activating factor antagonist WEB 2086BS. Transplantation 57:358-363, 1994
68. 68. MAKOWA L, CHAPMAN FA, CRAMER DV, QUIAN SG, SUN H, STARZL TE: Platelet-activating factor and hyperacute rejection: The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts. Transplantation 50:359-365, 1990
69. 69. MANGINO MJ, ANDERSON CB, MURPHY MK, TURK J: Renal allograft platelet activating factor synthesis during acute cellular rejection. J Lipid Med 4:69-81, 1991
70. 70. GRIÑO JM: BN 52021: A platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. Ann Intern Med 121:345-347, 1994
71. 71. JANCAR S, DEGIACCOBI G, MARIANO M, MENCIA-HUERTA JM, SIROIS P, BRAQUET P: Immune complex induced pancreatitis: Effect of BN-52021, a selective antagonist of platelet activating factor. Prostaglandins 35:757-770, 1988
72. 72. AIS G, LÓPEZ-FARRÉ A, GÓMEZ-GARRÉ DN, NOVO C, ROMEO JM, BRAQUET P, LÓPEZ-NovoA JM: Role of platelet-activating factor in hemodynamic derangements in an acute rodent pancreatic model. Gastroenterology 102:181-187, 1991
73. 73. ZHOU W, CHAO W, LEVINE BA, OLSON MS: Evidence for platelet activating factor as a late-phase mediator of chronic pancreatitis in the rat. Am J Pathol 137:1501-1508, 1990
74. 74. EMMANUELLI G, MOTRUCCHIO G, GAIA E, DUGHERA L, CORVETTI G, GUBETTA L: Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 134:315-326, 1989
75. 75. ALONSO R, MONTERO A, ARÉVALO MA, GARCIA LJ, SANCHEZ-VlCENTE C, RODRIGUEZ-NODAL F, LÓPEZ-NOVOA JM, CALVO JJ: Platelet activating factor mediates pancreatic function derangement in caerulein-induced pancreatitis. Clin Sci 87:85-90, 1994
76. 76. WANG J, DUNN MJ: Platelet activating factor mediates endotoxin-induced acute renal failure in rats. Am J Physiol 253:F1283-F1289, 1987
77. 77. TOLINS JP, VERCELLOTTI GM, WILKOWSKE M, HA B, JACOB HS, RAIJ L: Role of platelet activating factor in endotoxemic acute renal failure in the male rat. J Lab Clin Med 113:316-324, 1989
78. rd, ESSER KM, SLIVJAK M, FEUERSTEIN G: Platelet activating factor (PAF) and tumor necrosis factor-α (TNF-α) interactions in endotoxemic shock: Studies with BN 50739, a novel PAFG antagonist. J Pharmacol Exp Ther 255:256-263, 1990
79. 79. DOBROWSKY RT, VOYKSNER RD, OLSON NC: Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol 260:H1445-H1465, 1991
80. 80. MOZES T, HEILIGERS JPC, TAK CJ, ZIJLSTRA FJ, BEN-EFRAIM S, SAXENA PR, BONTA IL: Platelet activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Mediat 3:309-325, 1991
81. 81. MORELL GP, PlROTZKY E, ERARD D, DESMOTTES RM, BIDAULT J, DAMAIS C, BENVENISTE J: PAF-acether (platelet-activating factor) and interleukin-1-like cytokine production by lipopolysaccharide-stimulated glomeruli. Clin Immunol Immunopathol 46:396-405, 1988
82. 82. CHANG SW, FEDDERSEN CO, HENSON PM, VOELKEL NF: Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498-1509, 1987
83. 83. PINCKARD RN, MCMANUS M, HANAHAN DJ: Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor). Adv Inflamm Res 4:147-180, 1982
84. 84. MCMANUS LM, PINCKARD RN, FITZPATRICK FA, O'ROURKE RA, CRAWFORD MH, HANAHAN DJ: Acetyl glyceryl ether phosphoril choline: Intravascular alterations following intravenous infusion into the baboon. Lab Invest 45:303-307, 1981
85. 85. BAYLISS C, RENNKE HG, BRENNER BM: Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration. Kidney Int 12:344-353, 1977
86. 86. SCHOR N, ICHIKAWA I, RENNKE HG, TROY JL, BRENNER BM: Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 19:288-296, 1981
87. 87. SHARMA R, SHARMA M, LI JZ, MCCARTHY ET, SAVIN J: Direct effect of platelet activating factor on glomerular capillary permeability. Kidney Blood Press Res 20:25-30, 1997
88. 88. MENÉ P, SIMONSON MJ, DUNN MS: Physiology of the mesangium. Physiol Rev 64:1347-1370, 1989
89. 89. BARRIO V, ARRIBA G, LÓPEZ-NOVOA JM, RODRIGUEZ-PUYOL D: Atrial natriuretic peptide inhibits glomerular contraction induced by angiotensin II and platelet activating factor. Eur J Pharmacol 135:93-97, 1987
90. 2 synthesis, arachidonic acid release and contraction of cultured rat mesangial cells. J Clin Invest 73:1227-1231, 1984
91. 91. OLIVERA A, CARAMELO C, ARRIBA G, LAMAS S, RODRIGUEZ-PUYOL D, SCHRIER RW, RODRIGUEZ-BARBERO A, LÓPEZ NOVOA JM: Effect of atrial natriuretic factor and calcium antagonists on platelet activating factor-induced contraction and calcium mobilization in rat mesangial cells. J Cardiovasc Pharmacol 24:388-393, 1994
92. 92. WEISMAN SM, FELSEN D, VAUGHAN ED: Platelet-activating factor is a potent stimulus for renal prostaglandin synthesis: Possible significance in unilateral ureteral ligation. J Pharmacol Exp Ther 235:10-15, 1985
93. 93. BADR KF, DEBOER DK, TAKAHASHI K, HARRIS RC, FOGO A, JACOBSON HR: Glomerular responses to platelet-activating factor in the rat: Role of thromboxane A2. Am J Physiol 256:F35-F43, 1989
94. 94. ALESSANDRI MG, GIOVANNINI L, MIAN M, PALLA R, GATTAI V, CIANGHEROTTI A, BERTELLI A: PAF-induced histamine release in the isolated perfused rat kidney. Int J Tissue React 10:33-38, 1988
95. 95. BERTI F, ROSSONI G, BRAQUET P: Immune release of histamine and other lipid mediators from guinea-pig isolated kidney. Agents Actions 30:301-306, 1990
96. 96. RADKE KJ, SELKURT EE, WILLIS LR: The role of histamine H1 and H2 receptors in the canine kidney. Renal Physiol 8:100-111, 1985
97. 97. CAMPBELL WB, ITSKOVITZ HD: Effect of histamine and antihistamines on renal hemodynamics and function in the isolated perfused canine kidney. J Pharmacol Exp Ther 198:661-667, 1976
98. 98. SEDOR JR, ABBOUD HE: Histamine modulates contraction and cyclic nucleotides in cultured rat mesangial cells: Differential effects mediated by histamine H1 and H2 receptors. J Clin Invest 75:1679-1689, 1985
99. 99. SHUKLA S: Platelet-activating factor receptors and signal transduction mechanisms. FASEB J 6:2276-2301, 1992
100. 100. HONDA Z, NAKAMURA M, MIKI I, MINAMI M, WATANABE T, SEYAMA Y, OKADO H, TOH H, ITO K, MIYAMOTO T, SHIMIZU T: Cloning functional expression of platelet activating factor receptor from guinea pig lung. Nature 349:342-346, 1991
101. 101. KESTER M, MENÉ P, DUBYAK GR, DUNN MJ: Elevation of cytosolic free calcium by platelet activating factor in cultured rat mesangial cells. FASEB J 1:215-219, 1987
102. 2+] and phospholipase activity in mesangial cells. Am J Physiol 254:F87-F94, 1897
103. 103. KESTER M, THOMAS CP, WANG J, DUNN MJ: Platelet activating factor stimulates multiple signaling pathways in cultured rat mesangial cells. J Cell Physiol 153:244-255, 1992
104. 104. KESTER M: Platelet-activating factor stimulates phosphatidic acid formation in cultured rat mesangial cells: Roles of phospholipase D, diglyceride kinase, and de novo phospholipid synthesis. J Cell Physiol 156:317-325, 1993
105. 105. QIAN Z, DREWS LR: A novel mechanism for acetylcholine to generate diacylglycerol in brain. J Biol Chem 265:3607-3610, 1990